Apr 2, 2025 08:45AM
Feb 21, 2025 08:00AM
Feb 15, 2025 10:00PM
Jan 29, 2025 09:12AM
Jan 13, 2025 12:50PM
Jan 13, 2025 06:32AM
Jan 13, 2025 06:30AM Johnson & Johnson Strengthens Neuroscience Leadership with Acquisition of Intra-Cellular Therapies, Inc.
Jan 10, 2025 06:30AM
Jan 2, 2025 01:02PM
Jan 2, 2025 12:51PM
Dec 19, 2024 11:16AM
Dec 11, 2024 08:00AM
Dec 3, 2024 07:30AM
Nov 7, 2024 08:00AM Intra-Cellular Therapies Announces Presentations at the 2024 Psych Congress and NEI Congress
Nov 5, 2024 07:00AM
Nov 5, 2024 07:00AM
Oct 30, 2024 07:30AM
Sep 23, 2024 08:00AM
Aug 7, 2024 07:30AM
Jun 18, 2024 07:31AM
Jun 18, 2024 07:30AM Intra-Cellular Therapies Announces Positive Topline Results in Second Phase 3 Trial Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive Disorder
May 23, 2024 08:00AM
May 7, 2024 07:30AM
Apr 16, 2024 07:01AM
Apr 16, 2024 07:00AM
Apr 4, 2024 08:08AM
Feb 22, 2024 07:30AM
Dec 5, 2023 08:00AM Intra-Cellular Therapies Highlights Data Presentations at the American College of Neuropsychopharmacology Annual Meeting
Nov 2, 2023 07:30AM
Sep 11, 2023 08:00AM
Aug 3, 2023 07:30AM
May 31, 2023 08:00AM
May 4, 2023 07:30AM
Mar 28, 2023 07:03AM
Mar 28, 2023 07:00AM Intra-Cellular Therapies Announces Positive Topline Results from Study 403 Evaluating Lumateperone as Monotherapy in Patients with Major Depressive Disorder with Mixed Features and Bipolar Depression
Mar 1, 2023 07:30AM
Dec 8, 2022 08:00AM
Nov 3, 2022 07:30AM
Aug 9, 2022 07:30AM
Jun 13, 2022 08:00AM
May 10, 2022 07:30AM
Apr 25, 2022 07:03AM Intra-Cellular Therapies (ITCI) Granted FDA Approval of New Dosage Strengths for CAPLYTA
Apr 25, 2022 07:00AM
Mar 1, 2022 07:30AM
Dec 20, 2021 11:39AM
Dec 20, 2021 10:17AM
Dec 20, 2021 08:58AM
Dec 20, 2021 08:28AM
Dec 20, 2021 06:47AM Intra-Cellular Therapies (ITCI) Announces U.S. FDA Approval of CAPLYTA for Treatment of Bipolar Depression in Adults
Dec 20, 2021 06:47AM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All